{"id":968752,"date":"2026-05-29T16:33:34","date_gmt":"2026-05-29T20:33:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/"},"modified":"2026-05-29T16:33:34","modified_gmt":"2026-05-29T20:33:34","slug":"zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/","title":{"rendered":"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BOSTON, May  29, 2026  (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company\u2019s common stock (the \u201cInducement Awards\u201d) to four new employees pursuant to the Company\u2019s 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee\u2019s start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee\u2019s continued employment on each vesting date).<\/p>\n<p align=\"justify\">Each Inducement Award was approved by the Company\u2019s Compensation Committee and granted as an inducement material to the individual entering into employment with Zevra, in accordance with Nasdaq Rule 5635(c)(4).<\/p>\n<p align=\"justify\">\n        <strong>About Zevra Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra&#8217;s vision is realized through disciplined execution of its strategic plan and core values \u2014 patient centricity, integrity, accountability, innovation, and courage \u2014 which guide its efforts to deliver long-term value.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rviX97LxwUUV-Nd3dPjK5xPhjVZc_R9n4_fkq7tCCNjFK5jvh71zOoNLc2Jyw1QeMK0FBVn3ElTYS8TtGRpeGA==\" rel=\"nofollow\" target=\"_blank\">www.zevra.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OxxvvYjTxkotVgTwtTFCc-2kb-6G9OI-mY9cZMEtKGN1DTBC0frkjwm9VFgEcVIqIr3uq4Msx6oDRrhulZJ7gzPQOYRUkqv-AavF3tTh84TroilEnUfAwq2xUKtzn4wHU9Kbx9HC-z79BUa8piwYgIcRvlF8u88gvG6mBbiXFNYOsppf0sl21zE0QB9Z8VoReajcXSm3tdJR2h6_hVx0uTutcCfNXgyO_Z0Da99g3rco6EGBdoNH0kPt902eCP0d8MxtUPzxqjdaTdu5xUjq-mus7P3YO-9fB6ZiqJfF1No=\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K_7BDcvWg1vEAbTRctLRvy4fBinJNgw1HwOlfjTZPpn7wuvkhY87uG1xIJa8oKRZJz4HFdNZ_iJq0dW2FZtulPveVuGFv6kBN3aaNPBVMIl0Q0WG6zEG8DFnq1zAwLaUXTLU8cBU8sbZjmwcQ7NzJ4WHi69MyabA4k2J87G5prohFRMvkMppUrCpxUafHa-QEw6DTEBXMNF5_lzEHbVi6fZXfWAaooXFygbso2AbQdc-iBrCJDYp80ZXJOK5fABCw-ZkY0Vjvv_r5CUv_If1HA==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Caution Concerning Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the \u201cRisk Factors\u201d section of Zevra\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026 and Zevra\u2019s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 6, 2026, and Zevra&#8217;s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.<\/p>\n<p>\n        <strong>Investor Contact<\/strong>\n      <\/p>\n<p>Nichol Ochsner\u00a0<br \/>+1 (732) 754-2545\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z1GNTAs4efb52lnj2Vng33Uul4DgPhI6dxyNQF7XkD_AF-AEfkbkI8tiwRg1A5fmJt2fKrkiR7iPQnXGhQttIheMcnybdHT8jExH_OyYWAI=\" rel=\"nofollow\" target=\"_blank\">nochsner@zevra.com<\/a><strong>\u00a0<\/strong>\u00a0<\/p>\n<p>\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p>Julie Downs<br \/>+1 (508) 246-3230\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oQmi3LTIrQ-F0bD1RXoTjRcOQqH5yBPEpzVeAEurBXM1XN3RzQ0dVcRlkEGCYEWDhcsWwdicpdTJcV9WnKFvMi1OKPijj3Q5vjDWTQqLV9U=\" rel=\"nofollow\" target=\"_blank\">jdowns@zevra.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzQzNzU3NzctNmI1Mi00NGM5LTg5MzItNmFmNWE0NTdhMjcxLTEwMjkzMjgtMjAyNi0wNS0yOS1lbg==\/tiny\/Zevra-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, May 29, 2026 (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company\u2019s common stock (the \u201cInducement Awards\u201d) to four new employees pursuant to the Company\u2019s 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee\u2019s start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee\u2019s continued employment on each vesting date). Each Inducement Award was approved by the Company\u2019s Compensation Committee and granted as an &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-968752","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, May 29, 2026 (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company\u2019s common stock (the \u201cInducement Awards\u201d) to four new employees pursuant to the Company\u2019s 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee\u2019s start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee\u2019s continued employment on each vesting date). Each Inducement Award was approved by the Company\u2019s Compensation Committee and granted as an &hellip; Continue reading &quot;Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T20:33:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-05-29T20:33:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/\"},\"wordCount\":517,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/\",\"name\":\"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc=\",\"datePublished\":\"2026-05-29T20:33:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/","og_locale":"en_US","og_type":"article","og_title":"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"BOSTON, May 29, 2026 (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company\u2019s common stock (the \u201cInducement Awards\u201d) to four new employees pursuant to the Company\u2019s 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee\u2019s start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee\u2019s continued employment on each vesting date). Each Inducement Award was approved by the Company\u2019s Compensation Committee and granted as an &hellip; Continue reading \"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-29T20:33:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-05-29T20:33:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/"},"wordCount":517,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/","name":"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc=","datePublished":"2026-05-29T20:33:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODg1MyM3NjI3NzMxIzIwMTc3NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=968752"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968752\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=968752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=968752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=968752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}